Key Highlights
- Parse Biosciences acquires Biomage, integrating powerful data analysis software with its Evercode combinatorial barcoding technology.
- Richer suite of single cell data analysis tools now available, significantly reducing analysis time for researchers.
- Biomage’s Cellenics platform: A cloud-based RNA sequencing data analysis platform, reducing analysis times from six months to two weeks.
Source: Business Wire
Notable Quotes
- “Integrating the software into Parse’s portfolio of offerings will give our customers access to rich, dynamic exploration of single cell data in a shorter amount of time than anything currently available,” – Charles Roco, Co-founder & CTO at Parse Biosciences
- “The combination of Parse’s scalability and Biomage’s technology to speed analysis is an unbeatable combination that is going to have wide-ranging, positive implications for the single cell community,” – Adam Kurkiewicz, Co-founder & CEO at Biomage
SoH's Take
The acquisition of Biomage by Parse Biosciences marks a significant milestone in the single cell sequencing industry. This strategic move not only consolidates Parse’s position as a leader in this field but also demonstrates their commitment to enhancing the efficiency and accessibility of single cell data analysis. By integrating Biomage’s advanced data analysis tools with Parse’s innovative Evercode technology, researchers are poised to experience a transformation in how they approach single cell sequencing. This synergy promises to accelerate scientific discoveries, particularly in critical areas like cancer research, stem cell therapy, and immunology. It’s a bold step forward for Parse Biosciences, signaling a future where advanced scientific tools are more accessible and efficient, driving forward the frontiers of human health and scientific research.
